Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
8.95
+0.01 (0.11%)
At close: Oct 2, 2026, 4:00 PM EDT
9.03
+0.08 (0.84%)
After-hours: Oct 2, 2026, 7:59 PM EDT
Capricor Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
231
Market Cap
520.34M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 22.27M | -2.91M | -11.55% |
| Dec 31, 2023 | 25.18M | 22.63M | 886.81% |
| Dec 31, 2022 | 2.55M | 2.31M | 941.85% |
| Dec 31, 2021 | 244.90K | -65.35K | -21.06% |
| Dec 31, 2020 | 310.25K | -694.78K | -69.13% |
| Dec 31, 2019 | 1.01M | -666.33K | -39.87% |
| Dec 31, 2018 | 1.67M | -994.98K | -37.32% |
| Dec 31, 2017 | 2.67M | -1.33M | -33.32% |
| Dec 31, 2016 | 4.00M | -1.52M | -27.53% |
| Dec 31, 2015 | 5.52M | 730.95K | 15.27% |
| Dec 31, 2014 | 4.79M | 4.28M | 851.19% |
| Dec 31, 2013 | 503.23K | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 1.35M | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 231.24M |
| Allogene Therapeutics | 4.64M |
| Prime Medicine | 4.07M |
| Oculis Holding AG | 1.45M |
| Neurogene | 925.00K |
| ProKidney | 818.00K |
| Entera Bio | 42.00K |
| Altimmune | 31.00K |
CAPR News
- 8 days ago - Kaplan Fox & Kilsheimer LLP Alerts Capricor Therapeutics, Inc. (CAPR) Investors to Their Right to Seek Lead Plaintiff Status Before September 29, 2026 - Newsfile Corp
- 8 days ago - Kaplan Fox Urges Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to Seek a Leadership Role Before September 28, 2026 - GlobeNewsWire
- 10 days ago - Kaplan Fox & Kilsheimer LLP Encourages Investors of Capricor Therapeutics, Inc. (CAPR) to Contact the Firm Ahead of the Lead Plaintiff Deadline on September 29, 2026 - Newsfile Corp
- 10 days ago - Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Seeking Recovery to Contact the Firm Before September 28, 2026 - GlobeNewsWire
- 10 days ago - $CAPR Stock Notification: Capricor Therapeutics has been Sued for Securities Fraud after Clinical Data Issues Disclosed – Investors are Alerted to Contact BFA Law by September 28 - GlobeNewsWire
- 11 days ago - SHAREHOLDER REMINDER: Berger Montague Reminds Capricor Therapeutics, Inc. (CAPR) Investors of the September 28, 2026 Deadline - Newsfile Corp
- 12 days ago - These beaten-down stocks could bounce back in January, if history is any guide - Market Watch
- 15 days ago - Capricor Therapeutics, Inc. Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending September 28, 2026 Lead Plaintiff Deadline - PRNewsWire